Montana Antibiotic Stewardship Collaborative

Presented by Jack King, Director, MT Flex Program

MT ABS Collaborative

Goals:

Project Goal:

- Implement the core elements established by the Centers for Disease Control and Prevention (CDC) that represent an antibiotic stewardship program (7 inpatient and 4 outpatient) in 85% of the recruited hospitals and clinics in Montana by the end of 2018
- Outcome Goal:
 - Reduce C. difficile rates across Montana by 10% by December 2018. Baseline= 4.88
- Process Goal:
 - Establish Days of Therapy for antibiotic (NQF 2720) usage as a standard measure for inpatient facilities across Montana. Goal: 75% of recruited inpatient facilities will report this measure by December 2018.

Montana ABS Collaborative

Formed in February 2017

Mission:

Align and streamline strategies, services, education and hands on technical assistance to eliminate duplication of effort, reduce costs and deliver efficient, effective and high value-added ABS services to hospitals and clinics in Montana.

Benefits:

- Reduce duplication of efforts
- Promote continuity between inpatient, outpatient and long term care settings in the health systems
- Resources created/reviewed/promoted by multidisciplinary collaborative team
- Increase networking opportunities and access to all Montana healthcare providers

MT ABS Collaborative









Partners

- Montana Health Research & Education Foundation (MHREF) of Montana Hospital Association (MHA)
 - Health Research & Educational Trust (HRET)/ Hospital Improvement Innovation Network (HIIN)
 - States Targeting Reduction in Infections via Engagement (STRIVE)
 - MT Flex
- Montana Department of Public Health & Human Services (MDPHHS)
 - Communicable Disease Epidemiology
- Mountain Pacific Quality Health Quality Innovation Network (QIN)/Quality Improvement Organization (QIO) – Outpatient Antibiotic Stewardship
- Montana State University Office of Rural Health Area Health Education Centers (AHEC) – Small Rural Hospital Improvement Program (SHIP)
- University of Montana/Skaggs School of Pharmacy

MT ABS Collaborative, continued

Additional Stakeholders

- Montana Healthcare Association (Long Term Care)
- Montana Primary Care Association
- Montana Infectious Disease Physician's Network
- Montana Family Pharmacy Network
- Montana Pharmacists Association
- Montana Association of Professionals in Infection Control

MT ABS Collaborative, to date

- 54 facilities enrolled (out of 59 CAH and IPPS facilities)
 - 13/13 Inpatient Prospective Payment Systems (PPS)
 - 41/46 Critical Access Hospitals (CAHs)
- Recruited 85 outpatient settings
 - 89% implemented the 4 outpatient core elements
- Created and delivered joint education, resources and communication
 - Single MT ABS Resources webpage
 - MT ABS Blog 28 articles posted
 - Joint education
 - 10 webinars 385 participants
 - 3 in-person workshops 130 participants

MT ABS Collaborative Accomplishments

 National Healthcare Safety Network (NHSN) Annual Facility Survey (FAS)

	Data for CAHs	2016	2017
/	Reporting: Submitted Facility Annual Survey (FAS)	18/48 (37.5%)	34/48 (71%)
	Performance: Implemented All 7 Core Measures	7/18 (39%)	17/34 (50%)

- Established statewide C. difficile clinical pathway
- Established baseline data for evaluation measures
- Created ABS Tracking Tool

MT ABS Collaborative, again

Next Cycle:


- Expanded Training
 - Montana Echo Utilizing State Infectious Disease Physician Network
 - Statewide Clinical Pathway for Urinary Track Infections (UTIs)
 - Systemized and standardized "Actions" based upon universal Days of Therapy measures

ABS Tracking Tool

ABS Tracking Tool Development

- Goal: Create a tool that can be easily modified by the user to meet the needs of any ABS program - beginning, intermediate or advanced
- Developed in recognition that most hospitals would not be able to attain electronic submission of AU/AR data to NHSN
- Allows users to track additional core elements of ABS
- Provides reports for ABS teams/Hospital Staff
- Utilizes drop down menus when possible to promote consistency and ease of use
- Kitty Strowbridge, St. Luke Community Healthcare, Ronan, MT found a tracking tool that would become the foundation: Rochester Patient Safety C. difficile Prevention Collaborative Antibiotic Tracking Worksheet
- Tool Development: Jamie Schultz, MT Flex Program
- Collaboration:
 - Jamie, Kitty and St. Luke's Infection Preventionist, Brooke Pieper, with the help of Tom Vincent from Mountain Pacific Quality Health worked to modify the tool to align with NHSN AUR module measures & definitions and track best practices for an ABS program in a user friendly format

The Tool Contents



- Instructions & Definitions
- Facility ABX Data- The actual data collection spreadsheet
- Days Present by Location- the table for entering Days Present for chart calculations
- Drop Down Selections
- Charts that are created:
 - ABX Rate
 - Days of Therapy (DOT) Rate
 - ABX by Provider
 - ABX Class Utilization

Instructions & Definitions

Instructions for entering "Patient ABX Data":

Please fill each row out on the "Facility ABX Data" tab for any patient who is started on antibiotics for an infection.

• If the same patient was started on more than one antibiotic for the same infection, record each antibiotic on a separate row.

• Every time an antibiotic is stopped and restarted, start that antibiotic again on a new row.

• Ideally the information needed to complete this form will be obtained from the 24 hour report and chart review.

• Use drop down choices as much as possible. If your choice is not listed on the drop down menu, then type in your response.

• Any columns not highlighted or from "O" to "AB" may be hidden if the data is not going to be currently tracked. This may help reduce the size of the tool and eliminate unwanted columns.

• Yellow Highlighted columns are used for calculations, do not hide these columns if reducing size of data collection

Manually enter Patient Days Present data on the second tab in order to calculate ABX Rate, DOT Rate and ABX by Prescriber

Instructions for updating selections for "Drop Down Selections":

(For any column on the "Facility ABX Data" tab that has a drop-down menu available) Go to Drop Down Selections " tab (columns are in same order as on the "Facility ABX data" tab) To add additional selections: click on next available blank cell under the desired column heading and enter new selection- the box indicated the number of available fields for that column UTI Symptom Criteria UTI Assessment (revised Mcgeer criteria) OR click here for NHSN criteria UTI Culture Criteria To delete or edit current selections: highlight cell in list and type in new selection New selections should automatically appear in drop down menus on "Facility ABX Data" tab Columns filled in grey align with NHSN definitions- do not recommend changing these 1) Specimen collected from clean catch voided Patient with indwelling catheter: Patient without indwelling catheter: selections urine and positive culture with no more than 2 At least one of the symptoms listed below: g or tenderness o the testes, epididymis, or prostate species of microorganisms, at least one of which is *Fever, rigors or new-onset hyptension, with a bacterium of ≥10⁵ CFU/m no alternate site of infection and at least one of the symptoms below (new or increased) : Instructions for "Days Present by Location": OR *Acute change in mental status or acute pain or tenderness 2) Specimen collected from in/out straight functional decline, with no alternate catheter and positive culture with any number of diagnsos For patient care location-specific analyses, days present is calculated as the number of microorganism, at least one of which is a bacterium AND leukocytosis patients who were present for any portion of each day of a calendar month in any of ≥10² CFU/m *New-onset suprapubic pain or CVA pain or OR patient care location. tenderness 3) Specimen collected from an indwelling catheter* *Purulent discharge from around the otoms below (new or increased): and positive culture with ≥10⁵ CFU/m of any catheter Days Present per month will need to be manually added monthly on "Days Present by microorganism or acute pain, swelling or tenderness of the Location" tab. Use daily census for each location to calculate monthly total. testes, epididymis, or prostate *If catheter has been in place for >2 weeks, change catheter before obtaining urine sample

Definitions:

1) DOT = Days of Antibiotic Therapy 2) Fever = temp of 100 F, repeated > 99F or > 2 degrees above baseline 3) Urinary tract symptoms = dysuria, new onset incontinence, new onset frequency, urgency, suprapubic pain, gross hematuria, and costovertebral (CVA) pain or tenderness

- Detailed instructions for:
 - Entering Data on the spreadsheet
 - Definitions of spreadsheet elements
 - McGeer's Criteria for UTI Symptoms and Assessment
 - Link to NHSN's UTI Criteria
 - What needs to be entered for "Patient Days Present"
 - Customizing the Drop Down Selections

Facility ABX Data: Patient & Antibiotic Utilization Information

		Set No To We To <thw th="" to<=""> We To <</thw>	 		 > March Su Mo Tu W 25 20 27 2 4 5 6 7 11 12 13 1 18 19 202 25 26 27 2 26 27 2 1 2 3 4 	0 Th Fr Sa 1 2 3 8 9 10 4 15 16 17 1 22 23 24 8 9 31				 > Janua Su Mo Tu W 31 1 2 3 7 8 9 11 14 15 16 11 21 22 23 2 28 29 30 3 4 5 6 7 	Th Fr 8a 4 5 6 0 11 12 13 7 18 19 20 4 25 26 27 1 1 2 3		
	Dana Dana	Calendar or enter			Click on cell and select		Dana Dana	Automotivelly Resultated	0	Click on cell and select da		Calculated from ABX	00
Enter Patient Name, #, etc. Patient Identifier	Drop Down Patient Location Upon Admit	<u>manually</u> <u>Date Admitted to</u> <u>Hospital</u>	Patient Status upon Admit	Drop Down During stay, if patient status changed, what to?	enter manually (cells o Date of Status Change	ne formatted for date) Date Discharged from Hospital	Drop Down Antibiotic Name	Automatically Populated Antibiotic Class	Drop Down Route ABX Administered	manually (cells are ABX Start Date	formatted for date) Abx End Date	dates DOT	Drop Down Prescriber
Patient 1	Acute Care (Obs, Acute, Med/Surg, Skille		Observation	Acute Care/Med Surg	3/8/2018		AMPHOTERICIN B LIPOSOMAL	Polyenes	IM	3/7/2018	03/09/18	3	Dr. 1
Patient 2	LTC	3/20/2018	LTC			3/29/2018	AMIKACIN	Aminoglycosides	Digestive	3/21/2018	03/23/18	3	Dr. 4
Patient 3	LTC	3/26/2018	LTC			3/30/2018	AMPICILLIN	Penicillins	Respiratory	3/27/2018	03/31/18	5	Dr. 3
Patient 4	Acute Care (Obs, Acute, Med/Surg, Skille		Acute Care/Med Surg	-		2/3/2018	AZTREONAM	Monobactams	IV	2/1/2018	02/03/18	3	Dr. 2
Patient 5	Acute Care (Obs, Acute, Med/Surg, Skille	2/6/2018	Acute Care/Med Surg	g Swing Bed	2/7/2018		AMPICILLIN	Penicillins	IV	2/6/2018	02/10/18	5	Dr. 1
Patient 6	LTC	2/12/2018				2/23/2018	ZANAMIVIR	Neuraminidase inhibitors	Digestive	2/12/2018	02/23/18	12	Dr. 4
Patient 7	LTC	2/26/2018				2/28/2018	TEDIZOLID	Oxazolidinones	Respiratory	2/26/2018	02/28/18	3	Dr. 3
Patient 8	LTC	1/1/2018				1/5/2018	TEDIZOLID	Oxazolidinones	IM	1/1/2018	01/05/18	5	Dr. 2
	Acute Care (Obs, Acute, Med/Surg, Skille					1/19/2018	TEDIZOLID	Oxazolidinones	IV	1/8/2018	01/19/18	12	Dr. 1
Patient 10	Acute Care (Obs, Acute, Med/Surg, Skille	1/15/2018				1/17/2018	CLINDAMYCIN	Lincosamides	IV	1/15/2018	01/17/18	3	Dr. 4
Patient 11	LTC	4/2/2018				4/4/2018	LEVOFLOXACIN	Fluoroquinolones	Digestive	4/2/2018	04/04/18	3	Dr. 3
Patient 12	Acute Care (Obs, Acute, Med/Surg, Skille	5/22/2018				5/25/2018	IMIPENEM/ CILASTATIN	Carbapenems	Respiratory	5/22/2018	05/25/18	4	Dr. 2
Patient 13	LTC	5/8/2018				5/10/2018	ITRACONAZOLE	Azoles	IM	5/8/2018	05/10/18	3	Dr. 1
Patient 14	Acute Care (Obs, Acute, Med/Surg, Skille	4/10/2018				4/13/2018	ITRACONAZOLE	Azoles	IV IV	4/10/2018	04/13/18	4	Dr. 4
Patient 15	LTC	4/16/2018				4/19/2018	CEFOXITIN CEFOXITIN	Cephalosporins	Disective	4/16/2018	04/19/18	4	Dr. 3 Dr. 2
Patient 16	Acute Care (Obs, Acute, Med/Surg, Skille	5/28/2018				5/31/2018 6/8/2018	AMANTADINE	Cephalosporins	Digestive	5/28/2018	05/31/18	4	Dr. 2 Dr. 1
Patient 17 Patient 18	LTC	6/2/2018				3/16/2018	AMANTADINE	M2 ion channel inhibitors M2 ion channel inhibitors	Respiratory	6/3/2018	06/08/18	5	Dr. 1 Dr. 4
Patient 18 Patient 19	Acute Care (Obs, Acute, Med/Surg, Skille Acute Care (Obs, Acute, Med/Surg, Skille	3/14/2018				6/29/2018	AMANTADINE		IM	6/6/2018 6/6/2018	06/12/18	16	Dr. 4 Dr. 3
Facient 15	Acute Care (Obs, Acute, Med/Surg, Skille	6/21/2018				6/25/2018	Select ABX	Aminoglycosides #N/A		0/0/2018	06/21/18	1	01.5

Facility ABX Data

- Elements used for creating charts in yellow
- Interactive calendars
- Available drop down selections aligned with NHSN recommendations and measures
 - Antibiotic Name
 - Antibiotic Class- Auto populates from ABX name
 - Route Administered
 - Primary Indication
 - Symptoms
 - Culture Results
- Additional ABS Program Tracking
 - Calculated DOT
 - ABX by Prescriber
 - 48 Hour Re-assessment
 - Pharmacy Recommendations

Drop Down Selections


- Columns match Facility ABX Data columns
- Contents can be modified by user (instructions provided)
- Contents align with NHSN measures and recommendations

								hin the box) or remove items from to refresh all of your tables and o						
Patient Name	Patient Location Upon Admit	Date Admitted to <u>Hospital</u>	Patient Status upon <u>Admit</u>	During stay, if patient status changed, what to?	Date of Status Change	<u>Date Discharged</u> <u>from Hospital</u>	ABX Name	t Alter these Columns- Aligned with M <u>ABX Class</u>	NHSN <u>Route ABX Administered</u>	<u>ABX Start</u> <u>Date</u>	<u>Abx End</u> Date	DOT		Prescriber
	Acute Care (Obs, Acute, Med/Surg, Skilled Swing, OB)		Acute Care/Med Surg	Acute Care/Med Surg			AMANTADINE	M2 ion channel inhibitors	IV				Dr. 1	
	LTC		Observation	Observation			AMIKACIN	Aminoglycosides	IM				Dr. 2	
			Swing Bed	Swing Bed			AMOXICILLIN	Penicillins	Digestive				Dr. 3	
			LTC	LTC			AMOXICILLIN/ CLAVULANATE	B-lactam/ B-lactamase inhibitor combination	Respiratory				Dr. 4	
			ОВ	ОВ			AMPHOTERICIN B	Polyenes						
				test			AMPHOTERICIN B LIPOSOMAL							
							AMPICILLIN AMPICILLIN/ SULBACTAM	Penicillins B-lactam/ B-lactamase inhibitor combination						
							ANIDULAFUNGIN	Echinocandins						
							AZITHROMYCIN	Macrolides						
							AZTREONAM	Monobactams						
							CASPOFUNGIN	Echinocandins						

			F	ta	ables; if yo cility Temp	er any data in these green u have entered data in the plate and Days Present tabs, es will be automatically populated.					
	Month	Total ABX Start Date	Patient Days Present- Acute Care	Rate Per 1000		Month	Total ABX Start Date	Patient Days Present- LTC	Rate Per 1000		
	Jan	2	465	4.30		Jan	1	775	1.29		
	Feb	2	434	4.61		Feb	2	775	2.58		
	Mar	1	445	2.25		Mar	2	775	2.58		
ABX Rate Graph	Apr	1	425	2.35		Apr	2	775	2.58		
	May	2	427	4.68		May	1	775	1.29		
	Jun	2	0	#DIV/0!		Jun	1	0	#DIV/0!		
	Jul	0	0	#DIV/0!		Jul	0	0	#DIV/0!		
Datta	Aug	0	0	#DIV/0!		Aug	0	0	#DIV/0!		
RUIE	Sep	0	0	#DIV/0!		Sep	0	0	#DIV/0!		
NOIC	Oct	0	0	#DIV/0!		Oct	0	0	#DIV/0!		
	Nov	0	0	#DIV/0!		Nov	0	0	#DIV/0!		
Crouch	Dec	0	0	#DIV/0!		Dec	0	0	#DIV/0!		
	4.30 4.61 4.68 2.25 2.35 4.68 1.29										
		Acute Care (Obs, Acute, M Count of ABX Start Date 2 1 1	graphs to make sure a has been updated. T anywhere on these da	ny newly entered o Fo do this, right clic ta tables. Then se esh".	data ck elect	Patient Location Upon Adm Months Jan Feb Mar Apr	Count of ABX Start Date				

DOT Rate Graph





ABX Class Utilization by Month

						An	tibiotic	Class L	Jtilizatio	on					
3															
-															
2															
1	2									_					
-		1	1	1	1	1	1	1	1	1	1	1	1	1	1
0															
ľ	nes	des	lins	sms	tors	nes	nes	des	lins	les	Azoles	rins	sma	Azoles	rins
	Oxazolidinones	Lincosamides	Penicillins	Monobactams	hibit	Oxazolid inones	Polyenes	Aminoglycosides	Penicillins	Fluoroquinolones	Azı	Cephalosporins	Carbapenems	Azı	Cephalosporins
	xazo	Linco	<u> </u>	Mono	ase	xazol	_	gouin	۵.	oroqu		ephal	Carba		ep hal
	0			-	ninid	0		Am		Fluc		ð			ð
					Neuraminidase inhibitors										
		Jan		Fe				Mar			Apr			May	
Coun	t of Antil	biotic Class									e graphs to				
Mont			Antibiotic		🖵 Tota					itered data	has been ere on these	_			
∃ Jan			Oxazolidi Lincosam			2				elect "Refr					
lan To	otal		Encosam	lues		3									
🗆 Feb)		Penicillin	s		1		ar/M B 017	I 🗏 🖁	<mark>≽ - <u>A</u> - </mark>					
			Monobac			1		Feb 📭	⊆ору						
				nidase inhik	oitors	1		Mar 🚕	<u>F</u> ormat C	ells					
			Oxazolidinones b Total			-		May 📟 Jun 🖻	<u>R</u> efresh	4					
Feb T	otal		Oxazolidi			4									
Feb T = Ma			Oxazolidi Polyenes			4 1		test.							
			Polyenes Aminogly	rcosides		4 1 1	1	to t							
∃ Ma	r		Polyenes	rcosides		4 1 1 1	-1	11							
⊐ Ma Mar T	r Total		Polyenes Aminogly Penicillin	rcosides s		4 1 1 3		test.							
∃Ma	r Total		Polyenes Aminogly	rcosides s		4 1 1 3 1 1		test.							

MT ABS Collaborative, final

Resources

- MT ABS Resources webpage (link)
 - MT Antibiotic Stewardship Program Tracking tool- antibiotic usage (AU), Days of Therapy (DOT) spreadsheet and video/demo
 - MT ABS Collaborative and other ABS links and resources
 - Upcoming and previously presented MT ABS Collaborative educational events

MT ABS Blog (link)

MT Flex Contacts

- Jack King, Flex Grant Director jack.king@mtha.org
- For help with the ABS Tracking Tool:
 - Jamie Schultz, Rural Hospital Improvement Coordinator jamie.schultz@mtha.org